Showing results 1 to 1 of 1
| Issue Date | Title | Journal Title |
|---|---|---|
| 2026 | Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study | BREAST CANCER RESEARCH |